View Financial HealthUTime 配当と自社株買い配当金 基準チェック /06UTime配当金を支払った記録がありません。主要情報n/a配当利回り-833.3%バイバック利回り総株主利回り-833.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 05UTime Limited has completed a Follow-on Equity Offering in the amount of $1.2 million.UTime Limited has completed a Follow-on Equity Offering in the amount of $1.2 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Price\Range: $1.2 Discount Per Security: $0.072 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Price\Range: $0.7 Discount Per Security: $0.042 Transaction Features: Registered Direct Offeringお知らせ • May 02UTime Limited has filed a Follow-on Equity Offering in the amount of $1.2 million.UTime Limited has filed a Follow-on Equity Offering in the amount of $1.2 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: $1.2 Transaction Features: Registered Direct OfferingReported Earnings • Mar 19First half 2026 earnings releasedFirst half 2026 results: EPS: CN¥113. Revenue: CN¥99.5m (down 28% from 1H 2025). Net income: CN¥9.35m (up CN¥136.7m from 1H 2025). Profit margin: 9.4% (up from net loss in 1H 2025). The move to profitability was driven by lower expenses.New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-CN¥138m). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 233x increase in shares outstanding). Market cap is less than US$10m (US$6.08m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).分析記事 • Feb 04UTime Limited's (NASDAQ:WTO) Share Price Boosted 31% But Its Business Prospects Need A Lift TooThose holding UTime Limited ( NASDAQ:WTO ) shares would be relieved that the share price has rebounded 31% in the last...分析記事 • Nov 15The Market Doesn't Like What It Sees From UTime Limited's (NASDAQ:WTO) Revenues Yet As Shares Tumble 98%The UTime Limited ( NASDAQ:WTO ) share price has fared very poorly over the last month, falling by a substantial 98...お知らせ • Nov 05UTime Limited Explores Application of AI Technology in Health Data AnalysisUTime Limited outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies. UTime is developing AI-based algorithm models aimed at performing in-depth analysis of continuous physiological data collected from smart wearable devices such as watches and rings. Current research directions include: building hypertension risk assessment models by integrating multi-parameter data like blood pressure, heart rate, activity and sleep; and conducting trend assessments of users' cardiovascular system health status by analyzing features such as pulse wave morphology. The company explicitly states that all these AI analysis functions are intended to provide users with health trend insights and risk management references and are not substitutes for professional medical diagnosis.お知らせ • Nov 01UTime Limited Releases Smart Ring, Focusing on Sleep and Continuous Health MonitoringUTime Limited released its smart ring product. Utilizing the advantage of un noticeable wear, the product aims to provide users with nighttime and long-term continuous health data monitoring. This smart ring features a precise and compact design, capable of monitoring multiple physiological parameters including skin temperature, blood oxygen saturation (SpO2), respiratory rate, and heart rate variability (HRV). Its key application scenario is sleep quality assessment, aiming to generate more detailed sleep analysis reports by collecting data unobtrusively during user sleep. Additionally, the product focuses on daily activity tracking and female health cycle management, offering users more comprehensive health insights.Board Change • Oct 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Minfei Bao is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Oct 30UTime Limited Launches Smartwatch with Integrated Blood Pressure MonitoringUTime Limited announced the launch of a smartwatch with integrated blood pressure monitoring functionality, further expanding its product portfolio in the health technology sector. The product utilizes the Oscillo metric method, a market-validated measurement principle, and integrates a micro air pump and high-precision pressure sensor to provide users with a convenient blood pressure monitoring experience. It has obtained China NMPA Class II Medical Device Registration Certificate (Registration Certificate No.: Guangdong Instrument Note No. 20162070928). In addition to its core blood pressure monitoring feature, the watch also provides multi-dimensional health data references, including heart rate, blood oxygen saturation, sleep analysis, and multiple sports mode tracking. The product design balances wearing comfort with daily practicality and includes interactive features such as voice reminders.お知らせ • Oct 19UTime Limited has completed a Composite Units Offering in the amount of $25.000003 million.UTime Limited has completed a Composite Units Offering in the amount of $25.000003 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 22,727,275 Price\Range: $1.1 Discount Per Security: $0.099 Transaction Features: Registered Direct Offeringお知らせ • Sep 12+ 1 more updateUTime Limited Appoints Wang Tianlong as Chief Executive Officer, Effective September 9, 2025The Board of Directors of UTime Limited announced that on September 9, 2025, Wang Tianlong, male, 39 years old, Bachelor of Software Engineering from Hebei University, appointed as Chief Executive Officer.お知らせ • Aug 01UTime Limited announced delayed 20-F filingOn 07/31/2025, UTime Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.分析記事 • May 27Lacklustre Performance Is Driving UTime Limited's (NASDAQ:WTO) 44% Price DropUnfortunately for some shareholders, the UTime Limited ( NASDAQ:WTO ) share price has dived 44% in the last thirty...New Risk • Apr 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 48x increase in shares outstanding). Market cap is less than US$10m (US$4.79m market cap).お知らせ • Mar 27UTime Announces Reverse Share Split to Regain Compliance with Minimum Bid Price RequirementUTime Limited today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), at a ratio of 1-for-10, to be effective on or around the open of trading on March 31, 2025. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on or around Monday, March 31, 2025. Following the reverse share split, the Ordinary Shares will have a new par value of $0.001 per share and will continue to trade on Nasdaq under the symbol “WTO” with the new CUSIP number, G9411M124. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per Ordinary Share for continued listing on Nasdaq.Reported Earnings • Jan 16First half 2025 earnings released: CN¥192 loss per share (vs CN¥19.15 loss in 1H 2024)First half 2025 results: CN¥192 loss per share (further deteriorated from CN¥19.15 loss in 1H 2024). Revenue: CN¥138.4m (up 65% from 1H 2024). Net loss: CN¥127.3m (loss widened CN¥116.9m from 1H 2024).分析記事 • Jan 05Improved Revenues Required Before UTime Limited (NASDAQ:WTO) Stock's 26% Jump Looks JustifiedUTime Limited ( NASDAQ:WTO ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...分析記事 • Oct 22Little Excitement Around UTime Limited's (NASDAQ:WTO) Revenues As Shares Take 25% PoundingTo the annoyance of some shareholders, UTime Limited ( NASDAQ:WTO ) shares are down a considerable 25% in the last...New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Shareholders have been substantially diluted in the past year (over 32x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$11.9m market cap).お知らせ • Sep 10UTime Announces 1-for-25 Reverse Share Split Intended to Regain Compliance with the Minimum Bid Price RequirementUTime Limited announced that it will effect a reverse share split of its outstanding ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), at a ratio of 1-for-25, to be effective on or around the open of trading on September 11, 2024. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on or around September 11, 2024. Following the reverse share split, the Ordinary Shares will have a par value of $0.0001 per share and will continue to trade on Nasdaq under the symbol “WTO” with the new CUSIP number, G9411M116. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per ordinary share for continued listing on Nasdaq.お知らせ • Aug 26UTime Limited Develops Core Continuous Blood Pressure Measurement Technology SystemUTime Limited announced its collaboration on Circul VS, a core continuous blood pressure measurement technology system developed in partnership with strategic partner, Dr. Ehud Baron. Designed to offer patients an accurate and user-friendly continuous blood pressure monitoring solution, Circul VS facilitates early detection and long-term management, helping to reduce the risks associated with cardiovascular and cerebrovascular conditions. Circul VS features the BPwatch, Ring, and Smart Cradle, integrated into a sophisticated cloud-based network and service system. Unlike other systems on the market, Circul VS focuses on capturing rapid blood pressure fluctuations caused by changes in endothelial function and vascular tone—critical factors often neglected by competitors. Utilizing ultrasound sensing technology and intelligent algorithms, Circul VS provides continuous, real-time blood pressure waveform data with exceptional accuracy. This innovative technology is the result of comprehensive market research and extensive clinical studies. As part of this strategic collaboration, UTime has harnessed expertise in biomedical engineering and electronic technology to ensure the Circul VS system is not only precise but also stable and reliable in diverse clinical settings. Having undergone clinical trials in multiple partner hospitals, Circul VS has garnered positive feedback for its outstanding performance in the non-invasive monitoring space, offering systolic and diastolic pressure readings with accuracy approaching that of invasive techniques. During its development, Circul VS was tailored to meet the needs of different application scenarios—including hypertension screening for healthy individuals, long-term management for diagnosed hypertension patients, and acute monitoring for hospitalized patients. This adaptability ensures it meets the specific demands of various clinical environments. The launch of Circul VS marks a pivotal advancement in blood pressure monitoring technology. Together with Dr. Ehud Baron, UTime plans to continue refining this technology, aiming to enhance its intelligence and accuracy for widespread use in ICUs and other medical settings, ultimately improving patient care and quality of life.分析記事 • Aug 22UTime Limited's (NASDAQ:WTO) 116% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, UTime Limited ( NASDAQ:WTO ) shares have been powering on, with a gain of 116% in the...お知らせ • Aug 15UTime Regains Compliance with Nasdaq Minimum ClosingBid Price RuleUTime Limited announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s common stock has been at $1.00 per share or greater for the last 11 consecutive business days from July 26, 2024 to August 9, 2024. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.Reported Earnings • Aug 01Full year 2024 earnings released: CN¥1.95 loss per share (vs CN¥7.80 loss in FY 2023)Full year 2024 results: CN¥1.95 loss per share (improved from CN¥7.80 loss in FY 2023). Revenue: CN¥172.2m (down 14% from FY 2023). Net loss: CN¥32.3m (loss narrowed 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.分析記事 • Jul 03UTime Limited (NASDAQ:WTO) Stock Catapults 52% Though Its Price And Business Still Lag The IndustryUTime Limited ( NASDAQ:WTO ) shares have continued their recent momentum with a 52% gain in the last month alone. But...New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (121% increase in shares outstanding). Market cap is less than US$10m (US$3.38m market cap).分析記事 • Mar 20Revenues Working Against UTime Limited's (NASDAQ:WTO) Share Price Following 26% DiveUTime Limited ( NASDAQ:WTO ) shares have had a horrible month, losing 26% after a relatively good period beforehand...New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (US$3.79m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change).分析記事 • Dec 21Investors Aren't Buying UTime Limited's (NASDAQ:WTO) RevenuesUTime Limited's ( NASDAQ:WTO ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a buy right now compared...Board Change • Nov 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Minfei Bao is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 03UTime Limited announced delayed 20-F filingOn 08/01/2023, UTime Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.Board Change • Jul 23Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Xiaoqian Jia is the most experienced director on the board, commencing their role in 2023. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.お知らせ • Jul 21UTime Limited Announces Directorate ChangesUTime Limited announced on July 11, 2023, Mr. David Bolocan notified the Company of his resignation as a director of the Company, effective July 11, 2023. On July 11, 2023, Mr. Mo Zou notified the Company of his resignation as a director of the Company, effective July 11, 2023. on July 11, 2023, the board of directors of the Company appointed Ms. Na Cai to serve as a director and the Chairwoman of the Audit Committee of the Company, effective July 11, 2023. Ms. Cai, age 37, has over 10 years of financial and managerial experience in the technology and financial service industry. Since 2015, Ms. Cai has served as a director of Bluestone Securities (HK) Co., Limited and the Chief Financial Officer of Bluestone International Holdings (HK) Co. Ltd. She was the Finance Manager at Shenzhen Qianhai Sanchuan Asset Management Co. Ltd. between 2013 and 2015. From 2011 to 2013, Ms. Cai served as the Finance Controller of Shenzhen Qingfengyuan Environmental Protection Technology Co. Ltd. During her tenure, Ms. Cai demonstrated leadership and experience in financial management, strategy development, and operations. Ms. Cai received her bachelor’s degree from Taishan Medical College, now known as Shandong First Medical University. To fill in the vacancy created by the resignation of Mr. Zou, To fill in the vacancy created by the resignation of Mr. Bolocan, on July 11, 2023, the Board appointed Mr. Hailin Xie to serve as a director and the Chairman of Compensation Committee of the Company, effective July 11, 2023. Mr. Xie, age 43, has over 20 years of business development and managerial experience in the healthcare industry. Since 2000, Mr. Xie has established several businesses in the healthcare industry that research, develop, and manufacture health supplements in China. Mr. Xie is the Chairman of Guangxi Fuxingyi Investment Group and the President of Guangxi God Fly Investment Group. Mr. Xie attended Guangxi University, where he majored in marketing.New Risk • Jul 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$4.77m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (71% average weekly change). Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (US$4.77m market cap).分析記事 • Jul 12UTime Limited's (NASDAQ:UTME) Subdued P/S Might Signal An OpportunityYou may think that with a price-to-sales (or "P/S") ratio of 0.5x UTime Limited ( NASDAQ:UTME ) is a stock worth...Reported Earnings • Mar 27First half 2023 earnings released: CN¥1.75 loss per share (vs CN¥1.14 loss in 1H 2022)First half 2023 results: CN¥1.75 loss per share (further deteriorated from CN¥1.14 loss in 1H 2022). Revenue: CN¥127.8m (up 27% from 1H 2022). Net loss: CN¥14.3m (loss widened 53% from 1H 2022).Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 31Full year 2022 earnings released: CN¥4.76 loss per share (vs CN¥3.68 loss in FY 2021)Full year 2022 results: CN¥4.76 loss per share (further deteriorated from CN¥3.68 loss in FY 2021). Revenue: CN¥275.5m (up 12% from FY 2021). Net loss: CN¥38.8m (loss widened 134% from FY 2021).Board Change • Oct 29High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 25UTime Limited Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 20-FUnited Time Technology Co., Ltd. (UTime Limited) announced that it has received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Annual Report on Form 20-F for the fiscal year ended March 31, 2022 (the “Form 20-F”) in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1) (the “Rule”). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on July 29, 2022, the Company was unable to file its Form 20-F within the prescribed time period without unreasonable effort or expense. The extension period provided under Rule 12b-25 expired on August 16, 2022. Nasdaq has informed the Company that, under Nasdaq rules, the Company will be required to submit a plan to regain compliance with Rule 5250(c)(1) for the Staff’s consideration by no later than October 17, 2022, which is 60 calendar days from receipt of the Notice. If the Staff accepts the plan, the Staff may grant the Company an extension of up to 180 calendar days from the Form 20-F’s due date, or until February 13, 2023 to regain compliance. However, there can be no assurance that Nasdaq will accept the Company’s plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If the Staff does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company’s securities will be subject to delisting from Nasdaq. The Company is working diligently to complete its Form 20-F and intends to file the Form 20-F as soon as practicable to regain compliance with the Rules.お知らせ • Jul 30United Time Technology Co., Ltd. announced delayed 20-F filingOn 07/29/2022, United Time Technology Co., Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.お知らせ • May 29UTime Limited Announces Board ChangesUTime Limited announced that the company’s Board of Directors has appointed Weiyuan Wang to the Board. Mr. Wang will serve as an independent Board member and will also serve as the Chairman of the Nominating and Corporate Governance Committee and the member of the Audit Committee and the Compensation Committee of the Board of Directors. Mr. Wang joins the UTime Board of Directors following the voluntary resignation of Lawrence Eckles from the Board of Directors for personal reasons.Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 01First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CN¥6.96m from profit in 1H 2021). Profit margin: (down from 3.9% in 1H 2021). The decrease in margin was driven by lower expenses.Reported Earnings • Jul 25Full year 2021 earnings released: CN¥3.68 loss per share (vs CN¥4.82 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: CN¥246.9m (up 28% from FY 2020). Net loss: CN¥16.6m (loss narrowed 23% from FY 2020).決済の安定と成長配当データの取得安定した配当: WTOの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: WTOの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場UTime 配当利回り対市場WTO 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (WTO)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Electronic)0.8%アナリスト予想 (WTO) (最長3年)n/a注目すべき配当: WTOは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: WTOは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: WTOの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: WTOが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 13:18終値2026/05/22 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋UTime Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 05UTime Limited has completed a Follow-on Equity Offering in the amount of $1.2 million.UTime Limited has completed a Follow-on Equity Offering in the amount of $1.2 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Price\Range: $1.2 Discount Per Security: $0.072 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Price\Range: $0.7 Discount Per Security: $0.042 Transaction Features: Registered Direct Offering
お知らせ • May 02UTime Limited has filed a Follow-on Equity Offering in the amount of $1.2 million.UTime Limited has filed a Follow-on Equity Offering in the amount of $1.2 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 1,000,000 Price\Range: $1.2 Transaction Features: Registered Direct Offering
Reported Earnings • Mar 19First half 2026 earnings releasedFirst half 2026 results: EPS: CN¥113. Revenue: CN¥99.5m (down 28% from 1H 2025). Net income: CN¥9.35m (up CN¥136.7m from 1H 2025). Profit margin: 9.4% (up from net loss in 1H 2025). The move to profitability was driven by lower expenses.
New Risk • Feb 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (39% average weekly change). Negative equity (-CN¥138m). Earnings have declined by 70% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 233x increase in shares outstanding). Market cap is less than US$10m (US$6.08m market cap). Minor Risk Latest financial reports are more than 6 months old (reported March 2025 fiscal period end).
分析記事 • Feb 04UTime Limited's (NASDAQ:WTO) Share Price Boosted 31% But Its Business Prospects Need A Lift TooThose holding UTime Limited ( NASDAQ:WTO ) shares would be relieved that the share price has rebounded 31% in the last...
分析記事 • Nov 15The Market Doesn't Like What It Sees From UTime Limited's (NASDAQ:WTO) Revenues Yet As Shares Tumble 98%The UTime Limited ( NASDAQ:WTO ) share price has fared very poorly over the last month, falling by a substantial 98...
お知らせ • Nov 05UTime Limited Explores Application of AI Technology in Health Data AnalysisUTime Limited outlined its ongoing exploration in the field of health data analysis, particularly the potential application of artificial intelligence (AI) technologies. UTime is developing AI-based algorithm models aimed at performing in-depth analysis of continuous physiological data collected from smart wearable devices such as watches and rings. Current research directions include: building hypertension risk assessment models by integrating multi-parameter data like blood pressure, heart rate, activity and sleep; and conducting trend assessments of users' cardiovascular system health status by analyzing features such as pulse wave morphology. The company explicitly states that all these AI analysis functions are intended to provide users with health trend insights and risk management references and are not substitutes for professional medical diagnosis.
お知らせ • Nov 01UTime Limited Releases Smart Ring, Focusing on Sleep and Continuous Health MonitoringUTime Limited released its smart ring product. Utilizing the advantage of un noticeable wear, the product aims to provide users with nighttime and long-term continuous health data monitoring. This smart ring features a precise and compact design, capable of monitoring multiple physiological parameters including skin temperature, blood oxygen saturation (SpO2), respiratory rate, and heart rate variability (HRV). Its key application scenario is sleep quality assessment, aiming to generate more detailed sleep analysis reports by collecting data unobtrusively during user sleep. Additionally, the product focuses on daily activity tracking and female health cycle management, offering users more comprehensive health insights.
Board Change • Oct 31High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Minfei Bao is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 30UTime Limited Launches Smartwatch with Integrated Blood Pressure MonitoringUTime Limited announced the launch of a smartwatch with integrated blood pressure monitoring functionality, further expanding its product portfolio in the health technology sector. The product utilizes the Oscillo metric method, a market-validated measurement principle, and integrates a micro air pump and high-precision pressure sensor to provide users with a convenient blood pressure monitoring experience. It has obtained China NMPA Class II Medical Device Registration Certificate (Registration Certificate No.: Guangdong Instrument Note No. 20162070928). In addition to its core blood pressure monitoring feature, the watch also provides multi-dimensional health data references, including heart rate, blood oxygen saturation, sleep analysis, and multiple sports mode tracking. The product design balances wearing comfort with daily practicality and includes interactive features such as voice reminders.
お知らせ • Oct 19UTime Limited has completed a Composite Units Offering in the amount of $25.000003 million.UTime Limited has completed a Composite Units Offering in the amount of $25.000003 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 22,727,275 Price\Range: $1.1 Discount Per Security: $0.099 Transaction Features: Registered Direct Offering
お知らせ • Sep 12+ 1 more updateUTime Limited Appoints Wang Tianlong as Chief Executive Officer, Effective September 9, 2025The Board of Directors of UTime Limited announced that on September 9, 2025, Wang Tianlong, male, 39 years old, Bachelor of Software Engineering from Hebei University, appointed as Chief Executive Officer.
お知らせ • Aug 01UTime Limited announced delayed 20-F filingOn 07/31/2025, UTime Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.
分析記事 • May 27Lacklustre Performance Is Driving UTime Limited's (NASDAQ:WTO) 44% Price DropUnfortunately for some shareholders, the UTime Limited ( NASDAQ:WTO ) share price has dived 44% in the last thirty...
New Risk • Apr 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 48x increase in shares outstanding). Market cap is less than US$10m (US$4.79m market cap).
お知らせ • Mar 27UTime Announces Reverse Share Split to Regain Compliance with Minimum Bid Price RequirementUTime Limited today announced that it will effect a reverse share split of its outstanding Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), at a ratio of 1-for-10, to be effective on or around the open of trading on March 31, 2025. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on or around Monday, March 31, 2025. Following the reverse share split, the Ordinary Shares will have a new par value of $0.001 per share and will continue to trade on Nasdaq under the symbol “WTO” with the new CUSIP number, G9411M124. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per Ordinary Share for continued listing on Nasdaq.
Reported Earnings • Jan 16First half 2025 earnings released: CN¥192 loss per share (vs CN¥19.15 loss in 1H 2024)First half 2025 results: CN¥192 loss per share (further deteriorated from CN¥19.15 loss in 1H 2024). Revenue: CN¥138.4m (up 65% from 1H 2024). Net loss: CN¥127.3m (loss widened CN¥116.9m from 1H 2024).
分析記事 • Jan 05Improved Revenues Required Before UTime Limited (NASDAQ:WTO) Stock's 26% Jump Looks JustifiedUTime Limited ( NASDAQ:WTO ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...
分析記事 • Oct 22Little Excitement Around UTime Limited's (NASDAQ:WTO) Revenues As Shares Take 25% PoundingTo the annoyance of some shareholders, UTime Limited ( NASDAQ:WTO ) shares are down a considerable 25% in the last...
New Risk • Sep 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (37% average weekly change). Shareholders have been substantially diluted in the past year (over 32x increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$11.9m market cap).
お知らせ • Sep 10UTime Announces 1-for-25 Reverse Share Split Intended to Regain Compliance with the Minimum Bid Price RequirementUTime Limited announced that it will effect a reverse share split of its outstanding ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), at a ratio of 1-for-25, to be effective on or around the open of trading on September 11, 2024. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market (“Nasdaq”) on or around September 11, 2024. Following the reverse share split, the Ordinary Shares will have a par value of $0.0001 per share and will continue to trade on Nasdaq under the symbol “WTO” with the new CUSIP number, G9411M116. The reverse share split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per ordinary share for continued listing on Nasdaq.
お知らせ • Aug 26UTime Limited Develops Core Continuous Blood Pressure Measurement Technology SystemUTime Limited announced its collaboration on Circul VS, a core continuous blood pressure measurement technology system developed in partnership with strategic partner, Dr. Ehud Baron. Designed to offer patients an accurate and user-friendly continuous blood pressure monitoring solution, Circul VS facilitates early detection and long-term management, helping to reduce the risks associated with cardiovascular and cerebrovascular conditions. Circul VS features the BPwatch, Ring, and Smart Cradle, integrated into a sophisticated cloud-based network and service system. Unlike other systems on the market, Circul VS focuses on capturing rapid blood pressure fluctuations caused by changes in endothelial function and vascular tone—critical factors often neglected by competitors. Utilizing ultrasound sensing technology and intelligent algorithms, Circul VS provides continuous, real-time blood pressure waveform data with exceptional accuracy. This innovative technology is the result of comprehensive market research and extensive clinical studies. As part of this strategic collaboration, UTime has harnessed expertise in biomedical engineering and electronic technology to ensure the Circul VS system is not only precise but also stable and reliable in diverse clinical settings. Having undergone clinical trials in multiple partner hospitals, Circul VS has garnered positive feedback for its outstanding performance in the non-invasive monitoring space, offering systolic and diastolic pressure readings with accuracy approaching that of invasive techniques. During its development, Circul VS was tailored to meet the needs of different application scenarios—including hypertension screening for healthy individuals, long-term management for diagnosed hypertension patients, and acute monitoring for hospitalized patients. This adaptability ensures it meets the specific demands of various clinical environments. The launch of Circul VS marks a pivotal advancement in blood pressure monitoring technology. Together with Dr. Ehud Baron, UTime plans to continue refining this technology, aiming to enhance its intelligence and accuracy for widespread use in ICUs and other medical settings, ultimately improving patient care and quality of life.
分析記事 • Aug 22UTime Limited's (NASDAQ:WTO) 116% Price Boost Is Out Of Tune With RevenuesDespite an already strong run, UTime Limited ( NASDAQ:WTO ) shares have been powering on, with a gain of 116% in the...
お知らせ • Aug 15UTime Regains Compliance with Nasdaq Minimum ClosingBid Price RuleUTime Limited announced that it received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of $1.00 per share. The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s common stock has been at $1.00 per share or greater for the last 11 consecutive business days from July 26, 2024 to August 9, 2024. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and this bid price deficiency matter is now closed.
Reported Earnings • Aug 01Full year 2024 earnings released: CN¥1.95 loss per share (vs CN¥7.80 loss in FY 2023)Full year 2024 results: CN¥1.95 loss per share (improved from CN¥7.80 loss in FY 2023). Revenue: CN¥172.2m (down 14% from FY 2023). Net loss: CN¥32.3m (loss narrowed 63% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 44% per year, which means it is performing significantly worse than earnings.
分析記事 • Jul 03UTime Limited (NASDAQ:WTO) Stock Catapults 52% Though Its Price And Business Still Lag The IndustryUTime Limited ( NASDAQ:WTO ) shares have continued their recent momentum with a 52% gain in the last month alone. But...
New Risk • Apr 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 48% per year over the past 5 years. Shareholders have been substantially diluted in the past year (121% increase in shares outstanding). Market cap is less than US$10m (US$3.38m market cap).
分析記事 • Mar 20Revenues Working Against UTime Limited's (NASDAQ:WTO) Share Price Following 26% DiveUTime Limited ( NASDAQ:WTO ) shares have had a horrible month, losing 26% after a relatively good period beforehand...
New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 41% per year over the past 5 years. Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Market cap is less than US$10m (US$3.79m market cap). Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change).
分析記事 • Dec 21Investors Aren't Buying UTime Limited's (NASDAQ:WTO) RevenuesUTime Limited's ( NASDAQ:WTO ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a buy right now compared...
Board Change • Nov 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. Director Minfei Bao is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 03UTime Limited announced delayed 20-F filingOn 08/01/2023, UTime Limited announced that they will be unable to file their next 20-F by the deadline required by the SEC.
Board Change • Jul 23Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Xiaoqian Jia is the most experienced director on the board, commencing their role in 2023. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
お知らせ • Jul 21UTime Limited Announces Directorate ChangesUTime Limited announced on July 11, 2023, Mr. David Bolocan notified the Company of his resignation as a director of the Company, effective July 11, 2023. On July 11, 2023, Mr. Mo Zou notified the Company of his resignation as a director of the Company, effective July 11, 2023. on July 11, 2023, the board of directors of the Company appointed Ms. Na Cai to serve as a director and the Chairwoman of the Audit Committee of the Company, effective July 11, 2023. Ms. Cai, age 37, has over 10 years of financial and managerial experience in the technology and financial service industry. Since 2015, Ms. Cai has served as a director of Bluestone Securities (HK) Co., Limited and the Chief Financial Officer of Bluestone International Holdings (HK) Co. Ltd. She was the Finance Manager at Shenzhen Qianhai Sanchuan Asset Management Co. Ltd. between 2013 and 2015. From 2011 to 2013, Ms. Cai served as the Finance Controller of Shenzhen Qingfengyuan Environmental Protection Technology Co. Ltd. During her tenure, Ms. Cai demonstrated leadership and experience in financial management, strategy development, and operations. Ms. Cai received her bachelor’s degree from Taishan Medical College, now known as Shandong First Medical University. To fill in the vacancy created by the resignation of Mr. Zou, To fill in the vacancy created by the resignation of Mr. Bolocan, on July 11, 2023, the Board appointed Mr. Hailin Xie to serve as a director and the Chairman of Compensation Committee of the Company, effective July 11, 2023. Mr. Xie, age 43, has over 20 years of business development and managerial experience in the healthcare industry. Since 2000, Mr. Xie has established several businesses in the healthcare industry that research, develop, and manufacture health supplements in China. Mr. Xie is the Chairman of Guangxi Fuxingyi Investment Group and the President of Guangxi God Fly Investment Group. Mr. Xie attended Guangxi University, where he majored in marketing.
New Risk • Jul 19New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$4.77m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (71% average weekly change). Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (US$4.77m market cap).
分析記事 • Jul 12UTime Limited's (NASDAQ:UTME) Subdued P/S Might Signal An OpportunityYou may think that with a price-to-sales (or "P/S") ratio of 0.5x UTime Limited ( NASDAQ:UTME ) is a stock worth...
Reported Earnings • Mar 27First half 2023 earnings released: CN¥1.75 loss per share (vs CN¥1.14 loss in 1H 2022)First half 2023 results: CN¥1.75 loss per share (further deteriorated from CN¥1.14 loss in 1H 2022). Revenue: CN¥127.8m (up 27% from 1H 2022). Net loss: CN¥14.3m (loss widened 53% from 1H 2022).
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 31Full year 2022 earnings released: CN¥4.76 loss per share (vs CN¥3.68 loss in FY 2021)Full year 2022 results: CN¥4.76 loss per share (further deteriorated from CN¥3.68 loss in FY 2021). Revenue: CN¥275.5m (up 12% from FY 2021). Net loss: CN¥38.8m (loss widened 134% from FY 2021).
Board Change • Oct 29High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 25UTime Limited Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 20-FUnited Time Technology Co., Ltd. (UTime Limited) announced that it has received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Annual Report on Form 20-F for the fiscal year ended March 31, 2022 (the “Form 20-F”) in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1) (the “Rule”). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on July 29, 2022, the Company was unable to file its Form 20-F within the prescribed time period without unreasonable effort or expense. The extension period provided under Rule 12b-25 expired on August 16, 2022. Nasdaq has informed the Company that, under Nasdaq rules, the Company will be required to submit a plan to regain compliance with Rule 5250(c)(1) for the Staff’s consideration by no later than October 17, 2022, which is 60 calendar days from receipt of the Notice. If the Staff accepts the plan, the Staff may grant the Company an extension of up to 180 calendar days from the Form 20-F’s due date, or until February 13, 2023 to regain compliance. However, there can be no assurance that Nasdaq will accept the Company’s plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If the Staff does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company’s securities will be subject to delisting from Nasdaq. The Company is working diligently to complete its Form 20-F and intends to file the Form 20-F as soon as practicable to regain compliance with the Rules.
お知らせ • Jul 30United Time Technology Co., Ltd. announced delayed 20-F filingOn 07/29/2022, United Time Technology Co., Ltd. announced that they will be unable to file their next 20-F by the deadline required by the SEC.
お知らせ • May 29UTime Limited Announces Board ChangesUTime Limited announced that the company’s Board of Directors has appointed Weiyuan Wang to the Board. Mr. Wang will serve as an independent Board member and will also serve as the Chairman of the Nominating and Corporate Governance Committee and the member of the Audit Committee and the Compensation Committee of the Board of Directors. Mr. Wang joins the UTime Board of Directors following the voluntary resignation of Lawrence Eckles from the Board of Directors for personal reasons.
Board Change • Apr 27High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman of the Board Minfei Bao is the most experienced director on the board, commencing their role in 2018. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 01First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down CN¥6.96m from profit in 1H 2021). Profit margin: (down from 3.9% in 1H 2021). The decrease in margin was driven by lower expenses.
Reported Earnings • Jul 25Full year 2021 earnings released: CN¥3.68 loss per share (vs CN¥4.82 loss in FY 2020)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: CN¥246.9m (up 28% from FY 2020). Net loss: CN¥16.6m (loss narrowed 23% from FY 2020).